JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72.
The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains “fundamentally bullish” on the company, however.
Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
Related Posts
How Quickly Will The Dollar Collapse?- Slumping Used Car Prices Spell Disaster For Subprime Auto Securitizations
Watch Out,This Company’s Emphasis On Cloud Services May Spur Earnings Growth
US Equities – Are They Still In A Bull Market?- Capitalism Needs More Capitalists Like Mark Zuckerberg
EUR/USD Recovers As US Dollar Declines With Focus On US Q2 GDP
Leave A Comment